002390 信邦制药
交易中 11-16 10:33:30
资讯
新帖
简况
股市必读:信邦制药新发布《国浩律师(上海)事务所关于贵州信邦制药股份有限公司2026年第二次临时股东会的法律意见书》
证券之星 · 04:44
股市必读:信邦制药新发布《国浩律师(上海)事务所关于贵州信邦制药股份有限公司2026年第二次临时股东会的法律意见书》
股市必读:信邦制药(002390)11月10日董秘有最新回复
证券之星 · 11-11
股市必读:信邦制药(002390)11月10日董秘有最新回复
信邦制药:医疗服务板块的研发项目属于《科技伦理审查办法(试行)》规定的审查范围
证券之星 · 11-10
信邦制药:医疗服务板块的研发项目属于《科技伦理审查办法(试行)》规定的审查范围
信邦制药(002390)11月5日主力资金净卖出288.84万元
证券之星 · 11-06
信邦制药(002390)11月5日主力资金净卖出288.84万元
信邦制药(002390)9月30日股东户数6.55万户,较上期减少0.22%
证券之星 · 10-29
信邦制药(002390)9月30日股东户数6.55万户,较上期减少0.22%
图解信邦制药三季报:第三季度单季净利润同比增长56.96%
证券之星 · 10-29
图解信邦制药三季报:第三季度单季净利润同比增长56.96%
股市必读:信邦制药(002390)10月21日董秘有最新回复
证券之星 · 10-22
股市必读:信邦制药(002390)10月21日董秘有最新回复
股市必读:信邦制药新发布《关于控股子公司涉及诉讼的进展公告》
证券之星 · 10-09
股市必读:信邦制药新发布《关于控股子公司涉及诉讼的进展公告》
股市必读:信邦制药新发布《关于控股子公司涉及诉讼的进展公告》
证券之星 · 10-08
股市必读:信邦制药新发布《关于控股子公司涉及诉讼的进展公告》
信邦制药(002390)9月28日主力资金净买入1007.30万元
证券之星 · 09-29
信邦制药(002390)9月28日主力资金净买入1007.30万元
信邦制药营收连续下滑,上半年扣非净利润降幅近30%,“三驾马车”集体失速
市场资讯 · 08-29
信邦制药营收连续下滑,上半年扣非净利润降幅近30%,“三驾马车”集体失速
信邦制药(002390)6月30日股东户数6.57万户,较上期减少6.78%
证券之星 · 08-28
信邦制药(002390)6月30日股东户数6.57万户,较上期减少6.78%
信邦制药2026年半年报:经营现金流改善,营收净利双降
蓝鲸财经 · 08-28
信邦制药2026年半年报:经营现金流改善,营收净利双降
信邦制药(002390.SZ)发布半年度业绩,归母净利润9958.63万元,同比下降7.1%
智通财经 · 08-27
信邦制药(002390.SZ)发布半年度业绩,归母净利润9958.63万元,同比下降7.1%
信邦制药:近五年实施权益分派七次,累积派发现金红利(含税)6.32亿元
证券之星 · 06-29
信邦制药:近五年实施权益分派七次,累积派发现金红利(含税)6.32亿元
信邦制药收盘下跌3.33%,滚动市盈率36.33倍,总市值78.92亿元
金融界 · 2025-02-28
信邦制药收盘下跌3.33%,滚动市盈率36.33倍,总市值78.92亿元
暂无数据
公司概况
公司名称:
贵州信邦制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-04-16
主营业务:
贵州信邦制药股份有限公司的主营业务是医疗服务、医药流通、医药制造。公司的主要产品是益心舒胶囊、脉血康胶囊、关节克痹丸(独家品种)、银杏叶片、六味安消胶囊、贞芪扶正胶囊等药品、中药饮片及大健康产品。
发行价格:
33.00
{"stockData":{"symbol":"002390","market":"SZ","secType":"STK","nameCN":"信邦制药","latestPrice":2.95,"timestamp":1794796410000,"preClose":2.93,"halted":0,"volume":9729086,"delay":0,"changeRate":0.0068,"floatShares":1928000000,"shares":1944000000,"eps":0.0712,"marketStatus":"交易中","change":0.02,"latestTime":"11-16 10:33:30","open":2.91,"high":2.97,"low":2.91,"amount":28595000,"amplitude":0.0205,"askPrice":2.96,"askSize":3502,"bidPrice":2.95,"bidSize":3771,"shortable":0,"etf":0,"ttmEps":0.0712,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1794799800000},"marketStatusCode":2,"adr":0,"adjPreClose":2.93,"symbolType":"stock","openAndCloseTimeList":[[1794792600000,1794799800000],[1794805200000,1794812400000]],"highLimit":3.22,"lowLimit":2.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1943851868,"isCdr":false,"pbRate":0.84,"roa":"--","peRate":41.432584,"roe":"2.5%","epsLYR":0.0634,"committee":-0.085063,"marketValue":5734000000,"turnoverRate":0.005,"status":0,"floatMarketCap":5687000000},"requestUrl":"/m/hq/s/002390/tweets","defaultTab":"tweets","newsList":[{"id":"2683650948","title":"股市必读:信邦制药新发布《国浩律师(上海)事务所关于贵州信邦制药股份有限公司2026年第二次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683650948","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683650948?lang=zh_cn&edition=full","pubTime":"2026-11-16 04:44","pubTimestamp":1794775453,"startTime":"0","endTime":"0","summary":"公司公告汇总国浩律师(上海)事务所关于贵州信邦制药股份有限公司2026年第二次临时股东会的法律意见书国浩律师(上海)事务所就贵州信邦制药股份有限公司2026年第二次临时股东会的召集、召开程序、召集人资格、出席会议人员资格以及表决程序和表决结果出具法律意见书。2026年第二次临时股东会决议的公告贵州信邦制药股份有限公司于2026年11月13日召开2026年第二次临时股东会,会议采用现场投票与网络投票相结合的方式进行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600001517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0096","002390","BK0114","BK0004","BK0239","BK0146","BK0056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682311343","title":"股市必读:信邦制药(002390)11月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2682311343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682311343?lang=zh_cn&edition=full","pubTime":"2026-11-11 04:00","pubTimestamp":1794340843,"startTime":"0","endTime":"0","summary":"截至2026年11月10日收盘,信邦制药报收于3.02元,下跌0.33%,换手率0.71%,成交量13.65万手,成交额4120.77万元。董秘最新回复投资者: 董秘您好!当日关注点交易信息汇总:11月10日主力资金净流出39.88万元,占总成交额0.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100008115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0028","BK0096","BK0056","BK0114","002390","BK0004","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682781367","title":"信邦制药:医疗服务板块的研发项目属于《科技伦理审查办法(试行)》规定的审查范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2682781367","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682781367?lang=zh_cn&edition=full","pubTime":"2026-11-10 16:54","pubTimestamp":1794300849,"startTime":"0","endTime":"0","summary":"证券之星消息,信邦制药11月10日在投资者关系平台上答复投资者关心的问题。临床研究的伦理审查现由内部、合作医院还是外部机构承担?公司下属医院已按照国家有关法律、法规及监管的要求设立了伦理审查委员会,确保相关研发活动的合法合规。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111000033619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0096","BK0146","002390","BK0004","BK0056","BK0114","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681887823","title":"信邦制药(002390)11月5日主力资金净卖出288.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681887823","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681887823?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:23","pubTimestamp":1793928220,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月5日收盘,信邦制药报收于3.1元,上涨0.0%,换手率1.13%,成交量21.87万手,成交额6748.94万元。近5日资金流向一览见下表:信邦制药融资融券信息显示,融资方面,当日融资买入568.92万元,融资偿还686.55万元,融资净偿还117.64万元。信邦制药主营业务:医疗服务、医药流通及医药制造。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600009721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","002390","BK0056","BK0239","BK0114","BK0146","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679403196","title":"信邦制药(002390)9月30日股东户数6.55万户,较上期减少0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679403196","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679403196?lang=zh_cn&edition=full","pubTime":"2026-10-29 19:05","pubTimestamp":1793271950,"startTime":"0","endTime":"0","summary":"证券之星消息,近日信邦制药披露,截至2026年9月30日公司股东户数为6.55万户,较6月30日减少143.0户,减幅为0.22%。在中药行业个股中,信邦制药股东户数高于行业平均水平,截至9月30日,中药行业平均股东户数为5.34万户。从股价来看,2026年6月30日至2026年9月30日,信邦制药区间涨幅为14.58%,在此期间股东户数减少143.0户,减幅为0.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900045683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0056","BK0146","BK0239","002390","BK0028","BK0096","BK0114","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679241324","title":"图解信邦制药三季报:第三季度单季净利润同比增长56.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679241324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679241324?lang=zh_cn&edition=full","pubTime":"2026-10-29 02:55","pubTimestamp":1793213738,"startTime":"0","endTime":"0","summary":"证券之星消息,信邦制药2026年三季报显示,前三季度公司主营收入36.62亿元,同比下降14.16%;归母净利润1.7亿元,同比上升11.88%;扣非净利润1.38亿元,同比下降12.19%;其中2026年第三季度,公司单季度主营收入11.95亿元,同比下降15.91%;单季度归母净利润7083.38万元,同比上升56.96%;单季度扣非净利润6108.25万元,同比上升21.64%;负债率16.43%,投资收益3078.47万元,财务费用283.72万元,毛利率17.15%。财报数据概要请见下图:本文数据来源于信邦制药2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900003661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677609396","title":"股市必读:信邦制药(002390)10月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2677609396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677609396?lang=zh_cn&edition=full","pubTime":"2026-10-22 02:18","pubTimestamp":1792606691,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘,信邦制药报收于2.85元,上涨0.0%,换手率0.76%,成交量14.67万手,成交额4209.43万元。交易信息汇总资金流向10月21日主力资金净流出383.79万元,占总成交额9.12%;游资资金净流入40.08万元,占总成交额0.95%;散户资金净流入343.72万元,占总成交额8.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200001517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0004","BK0146","002390","BK0056","BK0114","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674002632","title":"股市必读:信邦制药新发布《关于控股子公司涉及诉讼的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674002632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674002632?lang=zh_cn&edition=full","pubTime":"2026-10-09 02:42","pubTimestamp":1791484932,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总:10月8日主力资金净流出255.83万元,占总成交额3.87%; 公司公告汇总:控股子公司科开医药因单位行贿罪被一审判处罚金400万元,占公司最近一期归母净利润的3.33%。公司公告汇总关于控股子公司涉及诉讼的进展公告贵州信邦制药股份有限公司于2026年10月8日发布公告,其控股子公司贵州科开医药有限公司因单位行贿罪被贵州省开阳县人民法院判处罚金人民币400万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900002476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0056","BK0028","BK0114","BK0146","BK0239","BK0004","002390","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673121730","title":"股市必读:信邦制药新发布《关于控股子公司涉及诉讼的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673121730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673121730?lang=zh_cn&edition=full","pubTime":"2026-10-08 02:13","pubTimestamp":1791396788,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘,信邦制药报收于2.96元,上涨1.37%,换手率1.04%,成交量20.04万手,成交额5919.7万元。当日关注点交易信息汇总:9月30日主力资金净流出452.88万元,占总成交额7.65%; 公司公告汇总:控股子公司科开医药因单位行贿罪被一审判处罚金400万元,占公司最近一期归母净利润的3.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0096","BK0146","002390","BK0004","BK0056","BK0114","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671269767","title":"信邦制药(002390)9月28日主力资金净买入1007.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671269767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671269767?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:08","pubTimestamp":1790644103,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月28日收盘,信邦制药报收于2.94元,上涨1.03%,换手率1.07%,成交量20.64万手,成交额6012.78万元。近5日资金流向一览见下表:信邦制药融资融券信息显示,融资方面,当日融资买入285.61万元,融资偿还383.5万元,融资净偿还97.89万元。信邦制药主营业务:医疗服务、医药流通及医药制造。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900008272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0114","BK0096","BK0146","BK0028","002390","BK0056","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663171470","title":"信邦制药营收连续下滑,上半年扣非净利润降幅近30%,“三驾马车”集体失速","url":"https://stock-news.laohu8.com/highlight/detail?id=2663171470","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663171470?lang=zh_cn&edition=full","pubTime":"2026-08-29 22:12","pubTimestamp":1788012720,"startTime":"0","endTime":"0","summary":"来源:深圳商报","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-29/doc-inipzani3427034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662669030","title":"信邦制药(002390)6月30日股东户数6.57万户,较上期减少6.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662669030","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662669030?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:47","pubTimestamp":1787910477,"startTime":"0","endTime":"0","summary":"证券之星消息,近日信邦制药披露,截至2026年6月30日公司股东户数为6.57万户,较3月31日减少4778.0户,减幅为6.78%。在中药行业个股中,信邦制药股东户数高于行业平均水平,截至6月30日,中药行业平均股东户数为5.16万户。从股价来看,2026年3月31日至2026年6月30日,信邦制药区间跌幅为18.89%,在此期间股东户数减少4778.0户,减幅为6.78%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0146","BK0114","002390","BK0239","BK0096","BK0004","BK0056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662367055","title":"信邦制药2026年半年报:经营现金流改善,营收净利双降","url":"https://stock-news.laohu8.com/highlight/detail?id=2662367055","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662367055?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:08","pubTimestamp":1787890101,"startTime":"0","endTime":"0","summary":"财报数据显示,报告期公司实现营业收入24.67亿元,同比下降13.29%;归母净利润0.99亿元,同比下降7.10%;扣非归母净利润0.77亿元,同比下降28.13%。从业务结构看,医药流通仍是公司最大收入来源,报告期实现营收17.46亿元,占比59.17%,但受药品集采降价及厂家配送权调整影响,该板块营收同比下降18.33%,毛利率下降1.92个百分点至7.08%。医疗服务板块实现营收7.30亿元,占比24.76%,同比下降7.65%,毛利率微升0.87个百分点至11.23%,主要得益于医院精细化运营及特色科室建设。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787882626298319619","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159399","002390","SPHQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662858970","title":"信邦制药(002390.SZ)发布半年度业绩,归母净利润9958.63万元,同比下降7.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662858970","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662858970?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:02","pubTimestamp":1787839365,"startTime":"0","endTime":"0","summary":"智通财经APP讯,信邦制药 发布2026年半年度报告,报告期内,公司实现营业收入24.67亿元,较上年同期下降13.29%;归属于上市公司股东的净利润9958.63万元,较上年同期下降7.1%;归属于上市公司股东的扣除非经常性损益的净利润7663.61万元,较上年同期下降28.13%;基本每股收益0.0525元。报告期内,公司医疗服务实现营业收入7.3亿元,较上年同期下降7.65%,其中肿瘤医院3.93亿元,综合医院3.38亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647669374","title":"信邦制药:近五年实施权益分派七次,累积派发现金红利(含税)6.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647669374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647669374?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:51","pubTimestamp":1782737488,"startTime":"0","endTime":"0","summary":"证券之星消息,信邦制药06月29日在投资者关系平台上答复投资者关心的问题。公司前期已通过实施股份回购、现金分红等方式以维护全体投资者利益,近五年实施完成两次股份回购计划,累计成交总金额6.55亿元;近五年实施权益分派七次,累积派发现金红利(含税)6.32亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900037847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390","BK0096","BK0114","BK0239","BK0146","BK0028","BK0004","BK0056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514310233","title":"信邦制药收盘下跌3.33%,滚动市盈率36.33倍,总市值78.92亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514310233","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514310233?lang=zh_cn&edition=full","pubTime":"2025-02-28 16:56","pubTimestamp":1740732969,"startTime":"0","endTime":"0","summary":"2月28日,信邦制药今日收盘4.06元,下跌3.33%,滚动市盈率PE达到36.33倍,总市值78.92亿元。从行业市盈率排名来看,公司所处的中药行业市盈率平均39.72倍,行业中值24.77倍,信邦制药排名第50位。贵州信邦制药股份有限公司是一家从事医疗服务、医药流通和医药制造的公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/28165648456457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0056","BK0146","BK0239","002390","BK0028","BK0096","BK0114","BK0004"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794796411930,"stockEarnings":[{"period":"1week","weight":-0.0393},{"period":"1month","weight":0.0103},{"period":"3month","weight":-0.0663},{"period":"6month","weight":-0.0428},{"period":"1year","weight":-0.2386},{"period":"ytd","weight":-0.0636}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贵州信邦制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"65521人(较上一季度减少0.22%)","perCapita":"29422股","listingDate":"2010-04-16","address":"贵州省黔南布依族苗族自治州罗甸县龙坪镇信邦大道48号","registeredCapital":"194385万元","survey":" 贵州信邦制药股份有限公司的主营业务是医疗服务、医药流通、医药制造。公司的主要产品是益心舒胶囊、脉血康胶囊、关节克痹丸(独家品种)、银杏叶片、六味安消胶囊、贞芪扶正胶囊等药品、中药饮片及大健康产品。","listedPrice":33},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信邦制药(002390)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信邦制药(002390)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信邦制药,002390,信邦制药股票,信邦制药股票老虎,信邦制药股票老虎国际,信邦制药行情,信邦制药股票行情,信邦制药股价,信邦制药股市,信邦制药股票价格,信邦制药股票交易,信邦制药股票购买,信邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信邦制药(002390)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信邦制药(002390)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}